期刊文献+

埃索美拉唑与奥美拉唑治疗胃溃疡的临床对比分析 被引量:5

下载PDF
导出
摘要 目的探讨埃索美拉唑与奥美拉唑治疗胃溃疡的临床价值。方法 120胃溃疡患者,根据治疗方法的不同分为观察组和对照组,每组60例。两组均给予阿莫西林联合克林霉素治疗,在此基础上,观察组加用埃索美拉唑治疗,对照组加用奥美拉唑治疗,比较两组治疗效果、幽门螺杆菌(Hp)根除率与不良反应情况。结果观察组总有效率为96.67%,高于对照组的85.00%,差异具有统计学意义(P<0.05);观察组Hp清除率为95.00%,高于对照组的81.67%,差异具有统计学意义(P<0.05);两组均有1例患者出现轻度皮肤过敏,停药后缓解。结论在阿莫西林与克林霉素用药的基础上,加用埃索美拉唑治疗胃溃疡的疗效稍优于加用奥美拉唑治疗,且安全性较高,值得临床应用。
作者 肖冬媛
出处 《中国现代药物应用》 2016年第1期136-137,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献5

二级参考文献43

  • 1崔梅花,杨友鹏,岳林,傅怡,乙国兴,牟方宏,杨桂彬,朱红霞,张秀丽.幽门螺杆菌血清抗体对埃索美拉唑四联疗法根除效果的影响研究[J].中国全科医学,2013,16(8):850-853. 被引量:16
  • 2楼雅卿,赵莉,张远.中国健康志愿者的奥美拉唑及其代谢物的药代动力学研究[J].中国临床药理学杂志,1994,10(1):14-21. 被引量:27
  • 3何庆玲,甘德春,陈扬,陈忠华,刘雪梅.三联疗法根除幽门螺杆菌的临床观察[J].实用医院临床杂志,2005,2(3):56-57. 被引量:3
  • 4Rabasseda X,Cole P. Esomep razole:A significant advance beyond omeprazole in the treatment of acid related disease[J]. J .Drugs Today (Barc), 2001,37 (11):767-781.
  • 5Kanazawa H, Okada A, HigakeM, et al. Stereosecific analysis of omep razole in human cytochrome P450 enzymes[J]. J Pharm Biomed Anal, 2003, 30(60) : 1817-1827.
  • 6Kendall MJ . Review article : esome prazole - the first proton pump inhibitor to be developed as an isomer [J]. J Aliment Pharmacol Ther,2003,17 (Suppl) : 1-4.
  • 7Dent J. Review article:pharmacology of esomeprazole and comparisons with omeprazole[J]. J Aliment Pharmaeol Ther,2003,17 (Suppl):5-9.
  • 8Hatlebakk JG. Review article: gastric acidity - comparison of esomeprazole with otherproton pump inhibitors [J]. J Aliment Pharmacol Ther,2003,17 (Suppl 1):5-10,16-17.
  • 9Gotoda T. Endoscopic resection of early gastric cancer[J]. Gastric Can- cer,2007 ,10(1): 1 - 11.
  • 10Bustamante M, Stollman N. The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review. J Clin Gastroenterol, 2000,30:7-13.

共引文献263

同被引文献45

  • 1邹华.埃索美拉唑与奥美拉唑治疗胃溃疡的药物经济学研究[J].医学信息(医学与计算机应用),2016,29(34):295-295. 被引量:4
  • 2牛春燕,罗金燕,王学勤,朱有玲.CYP2C19基因多态性对埃索美拉唑抑酸效应的影响[J].西安交通大学学报(医学版),2004,25(5):487-489. 被引量:13
  • 3Thomas CK,Vasileios A,Michel B,et al.Physical and chemical stability of esomeprazole sodium solutions[J].The Annals of:Pharmacotherapy,2008,42(9):1247.
  • 4Lou HY,Chang CC,Sheu MT,et al.Optimal dose regi- mens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism[J],Eur J Clin Pharmacol,2008,65(1):55.
  • 5Frelinger AL, Lee RD, Mulford DJ, et al.A randomized,2-period, crossover design study to assess the effectsof dexlansoprazole, lansoprazole, esomeprazole,andomeprazole on the steady-state pharmacokinetics andpharmacodynamics of clopidogrel in healthy volunteers[J].Journal of the American College of Cardiology, 2012,59(14): 1304-1311.
  • 6Lawson EB, Wu JC, Baldwin ,; RM, et al.Omeprazolelimited sampling strategies to predict area under theconcentration-time curve ratios : Implications forcytochrome P450 2C19 and 3A phenotyping[J].EuropeanJournal of Clinical Pharmacology ,2012,68 ( 4 ) : 407-413.
  • 7Kees MG, Steinke T, Moritz S, et al.Omeprazole impairsthe absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers[J].TheJournal of Clinical Pharmacology: Official Journal of theAmerican College of Clinical Pharmacology, 2012,52 ( 8 ):1265-1272.
  • 8黄垣.奥美拉唑药理机制分析及其临床应用探讨[J].医药前沿,2016,6 (8): 100-101.
  • 9Salimi A,Enferadi Z, Noorbakhash A, et al.Sensitiveamperometric detection of omeprazole and pantoperazole atelectrodeposited nickel oxide nanoparticles modified glassycarbon electrode[J].Journal of solid state electrochemistry,2012,16(4)-: 1369-1375.
  • 10Castillo GM, Nishimoto-Ashfield A, Banerjee AA,et al.Omeprazole and pgc-formulated heparin bindingepidermal growth factor normalizes fasting bloodglucose and suppresses insulitis in multiple low dosestreptozotocin diabetes model[J].Pharmaceutical research,2013,30 ( 11 ): 2843-2854.

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部